Aardvark Therapeutics
Financing Round
- Series C
Round Led by Symbiosis
Aardvark Therapeutics is a clinical stage biopharmaceutical company focused on developing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications. Founded in 2017, the company has now advanced ARD-101 to Phase II clinical trials. Aardvark has multiple other programs in its pipeline.
View Website
Modality
- Small Molecule
Indication
- Circulatory & Metabolic Disease
Development Status
- Phase 2